Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mistletoe compound enters clinical trials.

Martina Habeck

    Drug Discovery Today
    |February 5, 2003
    PubMed
    Summary

    A novel drug derived from mistletoe extract is now in clinical trials, showing potential as a new cancer treatment. This research explores its efficacy and safety for patients undergoing oncological therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Untangling the patterns of genetic variation.

    Drug discovery today·2005
    Same author

    New ray of hope for cancer patients.

    Drug discovery today·2004
    Same author

    Germany reattempts to spark innovation.

    Nature biotechnology·2004
    Same author

    Humboldt University beefs up technology transfer.

    Nature biotechnology·2004
    Same author

    Australia approves thalidomide.

    The Lancet. Oncology·2003
    Same author

    To approve or not approve?

    The Lancet. Oncology·2003

    Area of Science:

    • Oncology
    • Pharmacology
    • Biotechnology

    Background:

    • Mistletoe extracts have a long history in complementary cancer therapies.
    • Recombinant DNA technology allows for the production of specific, purified active compounds.

    Purpose of the Study:

    • To evaluate the safety and efficacy of a recombinant mistletoe extract drug in cancer patients.
    • To explore a novel therapeutic approach for various cancer types.

    Main Methods:

    • Clinical trials involving cancer patients.
    • Administration of the recombinant mistletoe extract drug.
    • Monitoring of patient outcomes, including tumor response and adverse events.

    Main Results:

    • The drug has successfully entered clinical trials.
    • Preliminary data suggests promising outcomes for cancer patients.
    • Further investigation into efficacy and side effect profiles is ongoing.

    Conclusions:

    • Recombinant mistletoe extract represents a potential new avenue in cancer therapy.
    • Clinical trials are crucial for validating its therapeutic role.
    • This approach may offer a targeted treatment option for oncological conditions.

    Related Experiment Videos